Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06333171
Other study ID # 00003872
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date July 2024
Est. completion date March 2028

Study information

Verified date March 2024
Source University of Arizona
Contact Andrea Horne
Phone 520-626-6456
Email ahh@arizona.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Many patients suffer from chronic non-healing wounds as well as acute wounds. There is a need to develop treatments to accelerate and improve healing of chronic and acute wounds. More research is needed to evaluate the role of 4-aminopyridine (4-AP), a promising new agent with an excellent safety profile, on wound healing. The investigational treatment will be used to evaluate the role of (4-AP) on the treatment of wounds to accelerate wound healing in healthy adults. The purpose of this study is to evaluate the role of 4-AP on the treatment of wounds to accelerate healing. The investigational treatment will be used to test the hypothesis that 4-AP can speed wound healing.


Description:

Worldwide, hundreds of millions of patients suffer from chronic non-healing wounds. In addition, most people will experience acute wounding at some point in their life. There is a need to develop agents to treat chronic and acute wounds. This need has intensified with the aging of the population, the rising incidence of diabetes and obesity, and the increasing number of patients undergoing treatment with medications that adversely affect wound healing. Through experiments performed on animals with 4-aminopyridine, (currently marketed by Acorda Healthcare, Inc. in slow-release form as AMPYRA®, and available in generic form proposed for use in this study), the investigators found striking effects on wounds in the standard rodent model used in the literature. In these experiments, animals with wounds held open with stents, healed faster with mass-adjusted human doses of 4-AP. All relevant markers of tissue regeneration were augmented with 4-AP treatment. These injuries are considered standard models, used for decades that correlate to those encountered in the human patients. The investigators found that: 1. 4-AP administration over just 21 days led to a large augmentation of wound healing at time points as early as three days post injury. 2. 4-AP treatment was associated with no adverse events in animals at the doses used consistent with our previous applications. 3. Numerous measures of wound healing at the cellular level showed quantifiable improvement with treatment at the tissue level. 4-AP is used in some of the most fragile of neurologically-ailing patients and is currently a mainline treatment in the setting of multiple sclerosis. Multiple sclerosis patients suffer a demyelinating disorder that causes the stripping of the myelin sheath from around neurons in the peripheral and central nervous system. The myelin covering allows for normal conduction of impulses and, without such covering, impulses are small, impaired, impeded, and ineffective. The recognition that crush injuries to nerves do not simply sever the axonal fibers but also demyelinate some population of nerve cells has led to the idea to study the treatment of peripheral nerve traumatic injuries in humans using 4-AP and this continues to be the subject of some of the investigator's other translational work There is extant literature demonstrating the positive effects of electrical stimulation in wound healing. Electrical stimulation of wounds has been shown to be effective in accelerating wound repair for diabetic foot ulcers and other chronic skin ulcers. Direct electrical stimulation of the skin is labor intensive, while 4-AP is more easily administered as an oral therapy. Thus, the recognition that re-innervation may improve healing in the wound bed - and that 4-AP has a differential, clinically relevant effect on nerves and wounds naturally leads to this application.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 68
Est. completion date March 2028
Est. primary completion date September 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Otherwise healthy adult patients without skin conditions effecting the skin of the axilla or upper inner arm. - Cognitive ability to evaluate wound healing, report sensory and motor deficit during examination. - Eligible for standard of care plan for wound closure by secondary intention (normal healing without intervention). - Adults subject aged 18-70 - Ability to give written informed consent. - Capable of safely coming in for follow up visits on all scheduled appointments. Exclusion Criteria: - History of multiple sclerosis, stroke or any other diagnosed neurological disorder - History of hypersensitivity to AMPYRA® or 4-aminopyridine - Current use of aminopyridine medications, including other compounded 4-AP - Suspected renal impairment based on the Choyke questionnaire. - History of difficult compliance with timely follow up - Patients outside the age range - Unable to provide informed consent. - Patients with a known history of a seizure disorder (4-AP overdose can, in selected cases, result in limited seizure activity). - Patients with a concomitant traumatic brain injury. - Patients unable to communicate. - Patients unwilling to complete the study requirements. - Patients currently taking organic cat-ion transporter 2 (OCT2) inhibitors, e.g. Cimetidine. - Pregnancy, breastfeeding or incarcerated individuals. - Non-English speaking - Patients unable or unwilling to take calibrated (with gauge) photographs of their wounds

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
4-Aminopyridine
Active study drug
Other:
Placebo
Placebo comparator

Locations

Country Name City State
United States University of Arizona Tucson Arizona

Sponsors (1)

Lead Sponsor Collaborator
John Elfar

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Return of skin integrity and wound closure after skin punch biopsy Axillary skin punch biopsies will be performed on healthy volunteers. Wound healing will be measured using visual assessment. 6 weeks
Secondary The effect of 4-AP on the hair number and growth at the skin punch biopsy site. The axillary skin punch biopsies will evaluated for the number of hair follicles and hair growth. 6 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04554212 - Blood Flow Restriction Training After Patellar INStability N/A
Suspended NCT02932176 - Machine Learning for Handheld Vascular Studies
Recruiting NCT04803253 - Study of the Social and Professional Reintegration Improvements Using a Set of Solutions for Upper Limb Amputation N/A
Completed NCT00116337 - Spinal Cord Stimulation to Restore Cough N/A
Completed NCT04438174 - Processed Amniotic Fluid (pAF) for the Treatment of Chronic Wounds Phase 1/Phase 2
Completed NCT03463720 - Outcome for Patients With War-Associated Extremity Wound Infection N/A
Completed NCT03113253 - TRANexamic Acid to Reduce Bleeding in BURN Surgery Phase 4
Not yet recruiting NCT05492903 - COMmunity of Practice And Safety Support for Navigating Pain (COMPASS-NP) N/A
Terminated NCT02909231 - One-year Patient Reported Outcomes Following Hospitalization for Trauma N/A
Completed NCT02432456 - Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients Phase 4
Completed NCT02744144 - Wound Bacterial Microbiota and Their Antibiotic Resistance N/A
Completed NCT02266771 - Impact of V.A.C. Veraflo Therapy in Wounds Requiring Debridement Within an Orthopedic Practice N/A
Completed NCT02394821 - Odor Management in Fungating Wounds Comparing Metronidazole and Polihexanide Phase 3
Not yet recruiting NCT01665963 - Efficacy of TopClosure(C)System in Healing Complicated Pacemaker Wounds N/A
Completed NCT00151112 - Comparison of Two Different Procedures for Plexus Anesthesia N/A
Not yet recruiting NCT03872544 - Short Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
Recruiting NCT04596124 - Effectiveness and Tolerability of Fitostimoline Plus Cream and Gauze vs Connettivina Bio Plus Cream and Gauze N/A
Recruiting NCT05800834 - Benefits of Morphine Gel for Pain Reduction in Patients With Cancer Wounds Phase 2
Enrolling by invitation NCT03880188 - Long Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
Terminated NCT04775316 - Prospective, International, Multicenter, Observational Study to Evaluate the Clinical Performance and Safety of a Silicone-coated Transparent Postoperative Dressing